Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;225(11):1886-1895.
doi: 10.1093/infdis/jiab102.

Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions

Kelly Kwong  1   2 , Andrea Benedetti  3   4 , Yvonne Yau  5   6 , Valerie Waters  5   7 , Dao Nguyen  1   2   8
Affiliations

Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions

Kelly Kwong et al. J Infect Dis. .

Abstract

Background: Antibiotics, such as inhaled tobramycin, are used to eradicate new-onset Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF) but frequently fail due to reasons poorly understood. We hypothesized that PA isolates' resistance to neutrophil antibacterial functions was associated with failed eradication in patients harboring those strains.

Methods: We analyzed all PA isolates from a cohort of 39 CF children with new-onset PA infections undergoing tobramycin eradication therapy, where 30 patients had eradicated and 9 patients had persistent infection. We characterized several bacterial phenotypes and measured the isolates' susceptibility to neutrophil antibacterial functions using in vitro assays of phagocytosis and intracellular bacterial killing.

Results: PA isolates from persistent infections were more resistant to neutrophil functions, with lower phagocytosis and intracellular bacterial killing compared to those from eradicated infections. In multivariable analyses, in vitro neutrophil responses were positively associated with twitching motility, and negatively with mucoidy. In vitro neutrophil phagocytosis was a predictor of persistent infection following tobramycin even after adjustment for clinical risk factors.

Conclusions: PA isolates from new-onset CF infection show strain-specific susceptibility to neutrophil antibacterial functions, and infection with PA isolates resistant to neutrophil phagocytosis is an independent risk factor for failed tobramycin eradication.

Keywords: Pseudomonas aeruginosa; antibiotic eradication therapy; cystic fibrosis; neutrophil phagocytosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pseudomona s aeruginosa isolates from patients with persistent infections exhibit lower neutrophil antibacterial functions compared to those from patients with eradicated infection. Neutrophil phagocytosis (A) and intracellular bacterial killing (B) of the persistent (n = 9 patients) group and the eradicated (n = 30 patients) group. The data were analyzed per patient by averaging the neutrophil results of all P. aeruginosa isolates from each patient. Results are shown as median and interquartile range. Statistical comparisons were performed using Mann–Whitney test (*P < .05, ***P < .001).
Figure 2.
Figure 2.
Neutrophil phagocytosis is significantly associated with intracellular bacterial killing. Association was calculated by Spearman correlation coefficient.
See this image and copyright information in PMC

References

    1. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015; 1:15010. - PMC - PubMed
    1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918–51. - PubMed
    1. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. ; Early Pseudomonas Infection Control (EPIC) Investigators . Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847–56. - PMC - PubMed
    1. Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 2014; 13:172–8. - PubMed
    1. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group . Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286–91. - PubMed

Publication types

MeSH terms